BRAF mutations in NSCLC – Market outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2020 To 2030
BRAF mutations are rare in non-small cell lung cancer (NSCLC), BRAF mutations are most commonly identified in lung adenocarcinoma. BRAFV600E is consistently described as the most common variant identified, present in more than 50% of cases with a BRAF mutation.
·
The BRAF Val600Glu (V600E)
mutation constitutes more than 90% of mutations in melanoma. V600E BRAF
mutation shows a great dependency on MEK activity and offers a rational
therapeutic strategy for this genetically defined tumor subtype.
· The use of vemurafenib and dabrafenib, agents that
block MAPK signaling in patients with melanoma and the BRAF V600E mutation, has
been associated with prolonged survival and progression-free survival. The
frequency of V600E BRAF mutation in lung adenocarcinoma is 1.5% to 2.8%.
The competitive
landscape of BRAF mutations in NSCLC includes country-specific approved and
pipeline therapies. Any asset/product-specific designation or review and
Accelerated Approval are tracked and supplemented with analyst commentary.
KOLs insights of BRAF
mutations in NSCLC across 8 MM market from the center of Excellence/ Public/
Private hospitals participated in the study. Insights around current treatment
landscape, epidemiology, clinical characteristics, future treatment paradigm,
and Unmet needs.
BRAF
mutations in NSCLC Market
Forecast: Patient Based Forecast Model (MS. Excel Based Automated
Dashboard) which Data Inputs with sourcing, Market Event, and Product Event,
Country specific Forecast Model, Market uptake and patient share uptake,
Attribute Analysis, Analog Analysis, Disease burden, and pricing scenario,
Summary, and Insights.
S. No Asset Company Stage
1 Encorafenib Array
BioPharma Phase 2
2 KIN-2787 Kinnate
Biopharma Phase 1
3 Dabrafenib Novartis
Pharmaceuticals Phase 2
Comments
Post a Comment